MARKET

BLTE

BLTE

Belite Bio, Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.14
+3.54
+12.83%
Closed 19:59 06/30 EDT
OPEN
26.77
PREV CLOSE
27.60
HIGH
31.95
LOW
26.77
VOLUME
110.28K
TURNOVER
--
52 WEEK HIGH
35.20
52 WEEK LOW
8.80
MARKET CAP
750.33M
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
Evoke, Zynerba top healthcare gainers; while 180 Life, Belite Bio lead losers' pack
Gainers: Evoke Pharma (EVOK) +52%. Zynerba Pharmaceuticals (ZYNE) +18%. LifeMD (LFMD) +13%. Vivos Therapeutics (VVOS) +12%. ACADIA Pharmaceuticals (ACAD) +11%. Losers: 180 Life Sciences (ATNF) -31%. Belite Bio (BLTE) -19%. VectivBio (VECT) -14%. biote (BTM...
Seekingalpha · 06/15 14:06
Mid-Morning Market Update: Markets Open Higher; US Retail Sales Drop In May
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Wednesday.
Benzinga · 06/15 14:03
IQ, CSSE and OWLT among mid-day movers
Gainers: Revlon (REV) +98%. biote (BTMD) +61%. Cepton (CPTN) +40%. Alpha Teknova (TKNO) +23%. New Oriental Education & Technology (EDU) +23%. Owlet (OWLT) +21%. Belite Bio (BLTE) +21%. Kaival Brands
Seekingalpha · 06/14 16:58
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy.
Benzinga · 06/14 16:07
Belite Bio jumps 13%, now trading 247% above IPO price
Drug developer Belite Bio (BLTE) shares jumped 13% Monday amid a significant sell-off in the broader market, trading 247% above its initial public offering price. Belite (BLTE) shares opened at
Seekingalpha · 06/13 18:21
70 Stocks Moving In Monday's Mid-Day Session
 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
Benzinga · 06/13 16:10
Day One Biopharmaceuticals leads healthcare gainers; ContraFect, SciSparc among losers
Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%.
Seekingalpha · 06/13 14:05
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and meta...
GlobeNewswire · 05/12 20:30
More
No Data
Learn about the latest financial forecast of BLTE. Analyze the recent business situations of Belite Bio, Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.17%
Pharmaceuticals & Medical Research
-0.21%
Key Executives
Chairman/Chief Executive Officer/Director
Yu-Hsin Lin
Chief Financial Officer/Director
Hao-Yuan Chuang
Chief Scientific Officer
Nathan Mata
Vice President
Ching- Chen Chiu
Director
Hung- Wei Chen
Director
Wan- Shan Chen
Independent Director
Gary Biddle
Independent Director
John Longo
Independent Director
Ita Lu
No Data
No Data
About BLTE
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. The Company is developing LBS-008 as an oral daily treatment for STGD1 and dry AMD. LBS-008 is a novel therapy targeting dry AMD and STGD1, which are untreatable conditions that cause progressive vision loss in affected individuals. LBS-008 is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye. The Company's LBS-009 is an anti- Retinol binding protein 4 (RBP4) oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Webull offers kinds of Belite Bio Inc (ADR) stock information, including NASDAQ:BLTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLTE stock methods without spending real money on the virtual paper trading platform.